Nautilus Biotechnology is trading at $2.04 (-10.70%) amid a sharp broader-market sell-off and weakness in biotech.
- No company-specific announcement explaining the November 5 decline was identified; the company’s latest listed release is its October 27 third-quarter results.
- The available evidence does not establish a specific trading-volume explanation.